Thermo Fisher to Acquire Mesa Biotech for $450M

 Thermo Fisher to Acquire Mesa Biotech for $450M

Thermo Fisher to Acquire Mesa Biotech for $450M

Shots:

  • Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while the transaction is expected to be completed in Q1’21
  • Mesa has developed & commercialized a PCR-based rapid POC testing platform for detecting infectious diseases. Messa’s technology inflates the availability of gold-standard nucleic acid PCR amplification to POC diagnostic
  • Mesa’s Accula Flu A/Flu B, RSV, and Strep A tests received the US FDA’s 510 (k) clearance while its Accula has received FDA’s EUA for SARS-CoV-2 IVD testing and is now available for use in patient care settings, providing results within 30min

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post